Synchronous metastases from colorectal cancer. Treatment and long-term survival compared to patients with metachronous metastases: a population-based study from Central Norway 2001–2015
Background: Reliable and modern information on primary evaluation, treatment, and long-term survival rates for patients with colorectal cancer (CRC) metastases are needed. Whether synchronous CRC metastases carry a worse prognosis than metachronous is still debated. Methods: Population-based study...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Journals Sweden
2025-06-01
|
| Series: | Acta Oncologica |
| Subjects: | |
| Online Access: | https://medicaljournalssweden.se/actaoncologica/article/view/42985 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850209095718535168 |
|---|---|
| author | Per Even Storli Rachel Genne Dille- Amdam Gaute Havik Skjerseth Mads Vikhammer Gran Tor Åge Myklebust Jon Erik Grønbech Erling A. Bringeland |
| author_facet | Per Even Storli Rachel Genne Dille- Amdam Gaute Havik Skjerseth Mads Vikhammer Gran Tor Åge Myklebust Jon Erik Grønbech Erling A. Bringeland |
| author_sort | Per Even Storli |
| collection | DOAJ |
| description | Background: Reliable and modern information on primary evaluation, treatment, and long-term survival rates for patients with colorectal cancer (CRC) metastases are needed. Whether synchronous CRC metastases carry a worse prognosis than metachronous is still debated.
Methods: Population-based study on 7,950 CRC patients from Central Norway, 2001– 2015. Of these, 1,843 (23.2%) had synchronous metastases and of radically operated patients with stage I–III disease 1,117 (20.1%) developed metachronous metastases. The treatment strategies and outcomes for patients with metastases were analyzed, stratified by three consecutive 5-year periods.
Results: Median and 3-year survival for patients with synchronous metastases were 11 months and 16.4%, compared to 17 months and 29.4% with metachronous metastases, p < 0.001 and p < 0.001, respectively. The subsets receiving supportive care only, had a median survival of 3–4 months. Patients with synchronous metastases and primary palliative chemotherapy had a median survival of 15 months compared to 18 months with metachronous metastases, p < 0.001. Neither groups improved survival across the study period. The 5-year survival for the 342/1,843 (18.6%) patients with synchronous metastases and curative intent treatment was 41.8% compared to 43.6% for the corresponding 422/1,117 (37.8%) patients with metachronous metastases, log-rank p = 0.281. Survival significantly improved for both these groups across the study period.
Interpretation: A key determinant of better survival for patients with metachronous CRC metastases compared to synchronous was a significantly higher proportion treated with curative intent. Survival for both patients with synchronous and metachronous metastases taken collectively steadily improved during the study period, driven by the increased proportions and improved survival for the subsets with curative intent treatment.
|
| format | Article |
| id | doaj-art-581fcd3f70fe45e8830b801d45719d0b |
| institution | OA Journals |
| issn | 1651-226X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Medical Journals Sweden |
| record_format | Article |
| series | Acta Oncologica |
| spelling | doaj-art-581fcd3f70fe45e8830b801d45719d0b2025-08-20T02:10:06ZengMedical Journals SwedenActa Oncologica1651-226X2025-06-016410.2340/1651-226X.2025.42985Synchronous metastases from colorectal cancer. Treatment and long-term survival compared to patients with metachronous metastases: a population-based study from Central Norway 2001–2015Per Even Storli0https://orcid.org/0000-0002-5072-4248Rachel Genne Dille- Amdam1https://orcid.org/0009-0001-4772-3236Gaute Havik Skjerseth2https://orcid.org/0009-0004-3308-5845Mads Vikhammer Gran3https://orcid.org/0000-0003-4771-7546Tor Åge Myklebust4https://orcid.org/0000-0003-4645-1635Jon Erik Grønbech5https://orcid.org/0000-0002-6034-867XErling A. Bringeland6https://orcid.org/0000-0002-1989-0029Department of Gastrointestinal Surgery, Clinic of Surgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, NorwayDepartment of Gastrointestinal Surgery, Clinic of Surgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, NorwayDepartment of Gastrointestinal Surgery, Clinic of Surgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, NorwayDepartment of Gastrointestinal Surgery, Clinic of Surgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, NorwayDepartment of Registration, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway; Department of Research and Innovation, Møre and Romsdal Hospital Trust, Ålesund, NorwayDepartment of Gastrointestinal Surgery, Clinic of Surgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, NorwayDepartment of Gastrointestinal Surgery, Clinic of Surgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, NorwayBackground: Reliable and modern information on primary evaluation, treatment, and long-term survival rates for patients with colorectal cancer (CRC) metastases are needed. Whether synchronous CRC metastases carry a worse prognosis than metachronous is still debated. Methods: Population-based study on 7,950 CRC patients from Central Norway, 2001– 2015. Of these, 1,843 (23.2%) had synchronous metastases and of radically operated patients with stage I–III disease 1,117 (20.1%) developed metachronous metastases. The treatment strategies and outcomes for patients with metastases were analyzed, stratified by three consecutive 5-year periods. Results: Median and 3-year survival for patients with synchronous metastases were 11 months and 16.4%, compared to 17 months and 29.4% with metachronous metastases, p < 0.001 and p < 0.001, respectively. The subsets receiving supportive care only, had a median survival of 3–4 months. Patients with synchronous metastases and primary palliative chemotherapy had a median survival of 15 months compared to 18 months with metachronous metastases, p < 0.001. Neither groups improved survival across the study period. The 5-year survival for the 342/1,843 (18.6%) patients with synchronous metastases and curative intent treatment was 41.8% compared to 43.6% for the corresponding 422/1,117 (37.8%) patients with metachronous metastases, log-rank p = 0.281. Survival significantly improved for both these groups across the study period. Interpretation: A key determinant of better survival for patients with metachronous CRC metastases compared to synchronous was a significantly higher proportion treated with curative intent. Survival for both patients with synchronous and metachronous metastases taken collectively steadily improved during the study period, driven by the increased proportions and improved survival for the subsets with curative intent treatment. https://medicaljournalssweden.se/actaoncologica/article/view/42985Colorectal cancerMetastasesSynchronousMetachronousmultidisciplinary team meetingmultidisciplinary team(MDT) |
| spellingShingle | Per Even Storli Rachel Genne Dille- Amdam Gaute Havik Skjerseth Mads Vikhammer Gran Tor Åge Myklebust Jon Erik Grønbech Erling A. Bringeland Synchronous metastases from colorectal cancer. Treatment and long-term survival compared to patients with metachronous metastases: a population-based study from Central Norway 2001–2015 Acta Oncologica Colorectal cancer Metastases Synchronous Metachronous multidisciplinary team meeting multidisciplinary team(MDT) |
| title | Synchronous metastases from colorectal cancer. Treatment and long-term survival compared to patients with metachronous metastases: a population-based study from Central Norway 2001–2015 |
| title_full | Synchronous metastases from colorectal cancer. Treatment and long-term survival compared to patients with metachronous metastases: a population-based study from Central Norway 2001–2015 |
| title_fullStr | Synchronous metastases from colorectal cancer. Treatment and long-term survival compared to patients with metachronous metastases: a population-based study from Central Norway 2001–2015 |
| title_full_unstemmed | Synchronous metastases from colorectal cancer. Treatment and long-term survival compared to patients with metachronous metastases: a population-based study from Central Norway 2001–2015 |
| title_short | Synchronous metastases from colorectal cancer. Treatment and long-term survival compared to patients with metachronous metastases: a population-based study from Central Norway 2001–2015 |
| title_sort | synchronous metastases from colorectal cancer treatment and long term survival compared to patients with metachronous metastases a population based study from central norway 2001 2015 |
| topic | Colorectal cancer Metastases Synchronous Metachronous multidisciplinary team meeting multidisciplinary team(MDT) |
| url | https://medicaljournalssweden.se/actaoncologica/article/view/42985 |
| work_keys_str_mv | AT perevenstorli synchronousmetastasesfromcolorectalcancertreatmentandlongtermsurvivalcomparedtopatientswithmetachronousmetastasesapopulationbasedstudyfromcentralnorway20012015 AT rachelgennedilleamdam synchronousmetastasesfromcolorectalcancertreatmentandlongtermsurvivalcomparedtopatientswithmetachronousmetastasesapopulationbasedstudyfromcentralnorway20012015 AT gautehavikskjerseth synchronousmetastasesfromcolorectalcancertreatmentandlongtermsurvivalcomparedtopatientswithmetachronousmetastasesapopulationbasedstudyfromcentralnorway20012015 AT madsvikhammergran synchronousmetastasesfromcolorectalcancertreatmentandlongtermsurvivalcomparedtopatientswithmetachronousmetastasesapopulationbasedstudyfromcentralnorway20012015 AT toragemyklebust synchronousmetastasesfromcolorectalcancertreatmentandlongtermsurvivalcomparedtopatientswithmetachronousmetastasesapopulationbasedstudyfromcentralnorway20012015 AT jonerikgrønbech synchronousmetastasesfromcolorectalcancertreatmentandlongtermsurvivalcomparedtopatientswithmetachronousmetastasesapopulationbasedstudyfromcentralnorway20012015 AT erlingabringeland synchronousmetastasesfromcolorectalcancertreatmentandlongtermsurvivalcomparedtopatientswithmetachronousmetastasesapopulationbasedstudyfromcentralnorway20012015 |